Objective: To explore the clinical efficacy of Zoledronic Acid Injection in the\ntreatment of postmenopausal osteoporosis with different bone turnover rates.\nMethods: A total of 63 patients diagnosed with postmenopausal osteoporosis\nwere included in this study. Each patient was administrated 5 mg/100mL Zoledronic\nAcid (Aclasta) intravenously once and then given a one-year prescription\nof 600 mg/d oral Caltrate. The bone turnover parameters ..... were measured prior to the injection of Zoledronic Acid\nwhile the bone mineral density (BMD) and the pain scores of each patient\nwere tested before treatment and after the one-year medication. On this basis,\nthe patients were divided into several groups according to their bone turnover\nrates for intergroup comparison of treatment outcomes. Results: BMD results\nand pain scores of all participants were significantly improved at different\nlevels after treatment. However, these improvements had no significant\ndifferences between the patients with high and low bone turnover rates. Conclusion:\nZoledronic Acid Injection can relieve bone pain, enhance the quality\nof life and increase the BMD in patients with postmenopausal osteoporosis,\nregardless of the bone turnover status.
Loading....